Brawn Biotech Ltd
NSE: BSE: 530207
₹21.60
(0%)
Mon, 25 May 2026, 10:49 am
Market Cap64.81M
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KBrawn Biotech Analysis
dividend
- Unable to calculate sustainability of dividends as Brawn Biotech has not reported any payouts.
- Unable to evaluate Brawn Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Brawn Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Brawn Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Brawn Biotech is profitable, therefore cash runway is not a concern.
- Brawn Biotech is profitable, therefore cash runway is not a concern.
- Brawn Biotech has no debt, it does not need to be covered by operating cash flow.
- Brawn Biotech has no debt, it does not need to be covered by short term assets.
- Brawn Biotech's cash and other short term assets cover its long term commitments.
- Brawn Biotech has no debt compared to 5 years ago when it was 0.1%.
- Brawn Biotech has no debt, therefore coverage of interest payments is not a concern.
- Brawn Biotech has no debt.
- Low level of unsold assets.
management
- The average tenure for the Brawn Biotech board of directors is less than 3 years, this suggests a new board.
- The average tenure for the Brawn Biotech management team is less than 2 years, this suggests a new team.
misc
- Brawn Biotech is not covered by any analysts.
- Brawn Biotech has significant price volatility in the past 3 months.
past
- Brawn Biotech's year on year earnings growth rate has been positive over the past 5 years.
- Brawn Biotech's 1-year earnings growth is less than its 5-year average (2.5% vs 17.6%)
- Brawn Biotech used its assets less efficiently than the IN Healthcare industry average last year based on Return on Assets.
- Brawn Biotech's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Brawn Biotech has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Brawn Biotech's earnings growth has not exceeded the IN Healthcare industry average in the past year (2.5% vs 14.4%).
value
- Brawn Biotech is good value based on assets compared to the IN Healthcare industry average.
- Brawn Biotech is good value based on earnings compared to the IN Healthcare industry average.
- Brawn Biotech is good value based on earnings compared to the India market.
- 530207 matched the India Market (-14.5%) over the past year.
- BSE:530207 is up 7.4% outperforming the Healthcare industry which returned 5.4% over the past month.
- BSE:530207 is up 7.4% along with the India market (8%) over the past month.
- Brawn Biotech's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Brawn Biotech's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- 530207 underperformed the Healthcare industry which returned 9.1% over the past year.